PiVily Quarterly Report
Operating models, AI credibility and the long data horizon
The quarter made one operating reality harder to ignore: future-ready safety systems would depend on regulatory translation and governance as much as new technology.
The quarter in one reading
Q1 2025 did not deliver one defining pharmacovigilance event. It reset three boundaries around the work: where regional requirements diverge, how AI credibility may be assessed, and how health-data access could evolve over a much longer implementation horizon.
This retrospective edition was reconstructed from official materials and completed on 11 August 2026. It describes the quarter; it does not imply contemporaneous publication.
Material signals
What moved—and why it mattered.
The UK operating model changed at the level that procedures must absorb.
From 1 January 2025, medicines approved in the UK moved under MHRA licensing, with pharmacovigilance requirements differentiated by Category 1 and Category 2 status. The framework addressed ICSR routes, PSURs, PASS, referrals, QPPV responsibilities and PSMF requirements.
The strategic issue was not a completely new discipline of PV. It was controlled translation: keeping a coherent global scientific position while ensuring that category-specific UK requirements remained visible in systems, procedures and records.
Can the organisation show, without relying on individual memory, which product category drives each reporting and implementation route?
AI credibility entered formal regulatory language.
FDA issued draft guidance in January 2025 proposing a risk-based credibility assessment framework for AI models used to generate information or data supporting regulatory decisions about safety, effectiveness or quality.
FDA: Draft guidance on AI supporting regulatory decision-making
The draft did not create a universal standard for every PV automation. It did establish a more disciplined vocabulary: context of use, model risk, credibility and evidence proportionate to the decision.
Does each material AI use have a defined decision context, accountable owner and evidence threshold—or only a technical description?
The European data horizon became clearer—and deliberately gradual.
The European Health Data Space Regulation entered into force on 26 March 2025. It established a framework for primary and secondary use of health data, while most obligations begin applying later and require implementing acts.
For PV, EHDS was a direction-of-travel signal rather than an immediate operational mandate. The opportunity is substantial, but access, interoperability, governance and fit-for-purpose use must develop together.
Is the organisation preparing for a richer data environment without treating future access as present-day evidence readiness?
Next-quarter watch
Questions to carry forward.
- How UK category rules settle into routine global-local governance
- Whether AI guidance becomes more use-case specific for safety operations
- The implementing architecture that will make EHDS operational over time
Method & source register
Trace the reading back to the record.
PiVily selects developments for system-level relevance to human pharmacovigilance. Facts are attributed to official publishers; interpretation is editorial. This is not an exhaustive jurisdictional change log or organisation-specific advice.